<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043820</url>
  </required_header>
  <id_info>
    <org_study_id>NL.55343.041.16</org_study_id>
    <secondary_id>2015-004483-11</secondary_id>
    <secondary_id>80-83600-98-40120</secondary_id>
    <nct_id>NCT03043820</nct_id>
  </id_info>
  <brief_title>Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder</brief_title>
  <acronym>RAPSODI</acronym>
  <official_title>Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iris Sommer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Julius Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rudolf Magnus Institute - University of Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GGZ Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GGZ Centraal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Altrecht GGZ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Reinier van Arkel Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is increasing clinical and molecular evidence for the role of hormones and specifically&#xD;
      estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator,&#xD;
      raloxifene, stimulates estrogen-like activity in brain and can improve cognition in older&#xD;
      adults. The present study will test the extent to which adjunctive raloxifene treatment&#xD;
      improved cognition and reduced symptoms in young to middle-age men and women with&#xD;
      schizophrenia.&#xD;
&#xD;
      110 patients with a schizophrenia spectrum disorder will be recruited in a multicenter&#xD;
      twelve-week, randomized, double-blind, placebo-controlled, parallel trial of adjunctive 120mg&#xD;
      raloxifene treatment in addition to their usual antipsychotic medications.&#xD;
&#xD;
      The investigators hypothesize that daily treatment with raloxifene 120 milligrams (mg) in&#xD;
      addition to antipsychotic treatment improves cognition, reduces psychotic symptoms, increases&#xD;
      social and personal functioning and reduces health care costs, as compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      Patients with a schizophrenia spectrum disorder experience substantial impairments in&#xD;
      multiple domains of everyday life, including the ability to maintain social relationships,&#xD;
      sustain employment, and live independently. These problems often persist, even after&#xD;
      successful treatment of psychosis. Currently, no consistent evidence exists for the efficacy&#xD;
      of interventions to reduce cognitive and negative symptoms, while in fact these are the&#xD;
      factors that determine functioning to a great extent.&#xD;
&#xD;
      Premenopausal women with schizophrenia have less psychotic and negative symptoms, and better&#xD;
      cognitive and social functioning, in comparison to men and older women. This has been related&#xD;
      to protective effects of estrogens in the brain. Administering estrogens has positive effects&#xD;
      on psychotic symptoms, but exerts long-term side effects, especially in men.&#xD;
&#xD;
      Raloxifene is a selective estrogen receptor modulator, with a beneficial side effect profile&#xD;
      in women and in men. It has been shown to be effective in reducing symptoms in postmenopausal&#xD;
      women with schizophrenia. Recently, positive results were found in premenopausal women and in&#xD;
      men. It is important to replicate these results in an independent sample and to investigate&#xD;
      the effects of raloxifene on functioning.&#xD;
&#xD;
      Hypotheses: Daily treatment with raloxifene 120 milligrams (mg) in addition to antipsychotic&#xD;
      treatment improves cognition, reduces psychotic symptoms, increases social and personal&#xD;
      functioning and reduces health care costs, as compared to placebo.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      The primary objective of this trial is to investigate the hypothesized beneficial effect of&#xD;
      raloxifene as compared to placebo when given for twelve weeks in addition to antipsychotic&#xD;
      medication to patients with a psychotic disorder. The investigators expect lower symptom&#xD;
      severity as measured with the Positive And Negative Symptom Scale (PANSS) and improvements of&#xD;
      cognitive functioning as measured with the Brief Assessment of Cognition in Schizophrenia&#xD;
      (BACS).&#xD;
&#xD;
      Secondary objectives include reducement of negative symptoms as measured with the Brief&#xD;
      Negative Symptom Scale (BNSS), improvement of Personal and Social Performance (using the&#xD;
      PSP-scale), reduction of thought disorder symptoms measures with the Thought And Language&#xD;
      Disorder-scale (TALD), reduction use of health care recourses using the institute for Medical&#xD;
      Technology Assessment's Medical Consumption Questionnaire (iMTA-MCQ), productivity using the&#xD;
      institute for Medical Technology Assessment's Productivity Cost Questionnaire (iMTA-PCQ),&#xD;
      improvement of quality of life using the EuroQol-5 dimensions scale (EQ-5D), improvement in&#xD;
      both speed and error rates in the Stroop test, reduction of comorbid depression using Beck's&#xD;
      Depression Inventory (BDI), improvement of language production and various hormonal and&#xD;
      inflammatory parameters.&#xD;
&#xD;
      Study design: Randomized placebo-controlled multicenter double-blind trial&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      110 men and women diagnosed with schizophrenia, schizoaffective or schizophreniform disorder,&#xD;
      or psychotic disorder not otherwise specified (DSM-IV 295.*)&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Patients will be randomized 1:1 to either 120mg raloxifene or placebo daily for a period of&#xD;
      12 weeks. Identical tablets will be administered.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      Primary outcomes are changes in symptom severity as measured with PANSS and changes in&#xD;
      cognition as measured with BACS. Secondary outcome are changes in negative symptoms (measured&#xD;
      with BNSS), changes in personal and social performance (measured with PSP), change in&#xD;
      severity of thought disorder (measured with TALD), quality of life (measured with EQ-5D), use&#xD;
      of healthcare and non-healthcare resources, comorbid depression (measured with BDI),&#xD;
      cognitive control (measured with a Stroop Test), language production (measured by analyzing&#xD;
      speech samples) and hormonal and inflammatory biomarkers.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: Use of raloxifene is associated with a small risk of side effects. The number of&#xD;
      patient visits will be limited and mainly requires time invested for physical examinations,&#xD;
      questionnaires and cognitive testing sessions (around 9 hours in total over the course of 9&#xD;
      months). Blood will be drawn at three occasions with negligible and known risks (e.g.&#xD;
      irritation). The burden and risks are acceptable while the benefits are expected to be&#xD;
      considerable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">July 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in symptom severity as measured with the Positive and Negative Symptom Scale (PANSS)</measure>
    <time_frame>Baseline, at 6 weeks of treatment, at 12 weeks of treatment (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapies on symptom severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cognitive functioning as measured with the Brief Assessment of Cognition in Schizophrenia</measure>
    <time_frame>Baseline, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapies on cognitive functioning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Personal and social performance measured with the Personal and Social Performance scale (PSP)</measure>
    <time_frame>Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapy on personal and social performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thought disorder severity as measured with the Thought And Language Disorder scale (TALD)</measure>
    <time_frame>Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapy on severity of thought disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Quality of Life as measured with the EQ-5D-5L</measure>
    <time_frame>Baseline, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapy on quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbid depression as measured with Beck's Depression Inventory (BDI).</measure>
    <time_frame>Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapy on comorbid depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of health-recourses as measured with the iMTA-MCQ</measure>
    <time_frame>Baseline, at 12 weeks (end of treatment) and 6 months follow-up</time_frame>
    <description>Effect of the study therapy on use of recourses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of non-health recourses as measured with the iMTA-PCQ</measure>
    <time_frame>Baseline, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapy on use of recourses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Language production assessment by analyzing speech samples</measure>
    <time_frame>Baseline and at 12 weeks of treatment (end of treatment)</time_frame>
    <description>Effect of the study therapy on free speech.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom severity as measured with the Brief Negative Symptom Scale (BNSS)</measure>
    <time_frame>Baseline, at 6 weeks, at 12 weeks (end of treatment) and 6 months after end of treatment (follow-up)</time_frame>
    <description>Effect of the study therapies on symptom severity.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hormonal biomarkers for predicting treatment response to raloxifene</measure>
    <time_frame>Baseline and at 12 weeks of treatment</time_frame>
    <description>Hormonal biomarkers (in women: prolactin, follicle stimulating hormone and 17-beta estradiol; in men: prolactin, 17-beta estradiol, testosterone and sex hormone binding globulin and c-reactive protein will be assessed in blood samples to examine whether these parameters predict treatment response to raloxifene augmentation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Deoxyribonucleic acid analysis for predicting treatment response to raloxifene</measure>
    <time_frame>Baseline and at 12 weeks of treatment</time_frame>
    <description>Single nucleotide polymorphism (SNP) analysis of estrogen receptor gene 1 (ESR1) SNP rs2234693, rs9340799, rs2144025 and UGT1A8 gene rs1042597.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <condition>Psychosis NOS</condition>
  <arm_group>
    <arm_group_label>Raloxifene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 2 tablets daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raloxifene</intervention_name>
    <description>Oral selective estrogen receptor modulator (SERM).</description>
    <arm_group_label>Raloxifene</arm_group_label>
    <other_name>Evista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets identical in form and color to intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform disorder,&#xD;
             schizoaffective disorder, or psychotic disorder NOS)&#xD;
&#xD;
          -  Capable of understanding the purpose and details of the study in order to provide&#xD;
             written informed consent;&#xD;
&#xD;
          -  On a stable dose of antipsychotic medication for at least two weeks;&#xD;
&#xD;
        For female patients:&#xD;
&#xD;
          -  Female patients who are sexually active must be willing and capable to use a&#xD;
             non-estrogenic contraceptive (intrauterine device, cervical cap, condom or diaphragm)&#xD;
             in case of sexual intercourse for the complete duration of the study;&#xD;
&#xD;
          -  Female patients with post coital uterine bleeding must have documented normal PAP&#xD;
             smear and pelvic examination in the preceding two years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing cardiovascular disease;&#xD;
&#xD;
          -  History of thrombo-embolic events;&#xD;
&#xD;
          -  History of breast cancer;&#xD;
&#xD;
          -  Familial tendency to form blood clots (such as familial factor V Leiden);&#xD;
&#xD;
          -  Use of vitamin K antagonists;&#xD;
&#xD;
          -  Use of cholestyramine or other anion exchange resins;&#xD;
&#xD;
          -  Hypertriglyceridemia (triglycerides &gt; 3 times the upper limit of normal (ULN));&#xD;
&#xD;
          -  Liver function or enzyme disorders (serum bilirubin, alkaline phosphatase (AF),&#xD;
             gamma-glutamyl transpeptidase (Î³ - GT), aspartate aminotransferase (ASAT) or alanine&#xD;
             aminotransferase (ALAT) &gt; 3 times the ULN as measured at baseline);&#xD;
&#xD;
          -  Severe kidney failure (eGFR &lt;30 ml/min as measured at baseline);&#xD;
&#xD;
          -  Use of any form of estrogen, progestin or androgen as hormonal therapy, or&#xD;
             antiandrogen including tibolone or use of phytoestrogen supplements as powder or&#xD;
             tablet in the past three months.&#xD;
&#xD;
        For female patients:&#xD;
&#xD;
          -  Abnormality observed during physical breast examination;&#xD;
&#xD;
          -  Pregnancy or breast feeding;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris Sommer, Prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Groningen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bob Oranje, Ass. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janna de Boer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Heringa SM, Begemann MJ, Goverde AJ, Sommer IE. Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Schizophr Res. 2015 Nov;168(3):603-13. doi: 10.1016/j.schres.2015.04.002. Epub 2015 Apr 23. Review.</citation>
    <PMID>25914107</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Iris Sommer</investigator_full_name>
    <investigator_title>Prof. dr. Iris Sommer</investigator_title>
  </responsible_party>
  <keyword>raloxifene</keyword>
  <keyword>selective estrogen receptor modulator (SERM)</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>psychosis</keyword>
  <keyword>cognition</keyword>
  <keyword>negative symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

